Anticancer properties of Viburnum
DOI:
https://doi.org/10.15584/ejcem.2018.1.8Keywords:
antitumor activity, Viburnum species, cytotoxic activityAbstract
Aim. The aim of this paper is to provide an overview of the anticancer properties of different species of Viburnum.
Material and methods. Forty nine papers that discuss the medicinal history and current research of Viburnum species as phytotherapeutic agent were used for this discussion.
Literature analysis. The results of scientific research conducted in vitro indicate that the compounds present in the extracts of Viburnum significantly affect the development of cancer cells such as leukemia, cervical cancer, breast, colon, lung, skin and stomach. This indicates that they may be used as a therapeutic agent to support oncological therapies.
Downloads
References
Winkworth RC. Viburnum phylogeny based on combined molecular data: implications for taxonomy and biogeography. Am J Botany. 2005;92:653–666.
Beikircher B, Mayr S. Intraspecific differences in drought tolerance and acclimation in hydraulics of Ligustrum vulgare and Viburnum lantana. Tree Physol. 2009;29(6):765-75.
Kollmann J, Grubb P. Viburnum lantana L. and Viburnum opulus L. (V.lobatum lam., Opulus vulgaris Borh.). J Ecol. 2002;90:1044-1070.
Paulauskas A, Žukauskienė J, Žiaukienė D, Česonienė L, Viškelis P. Differentiation of Viburnum accessions according to their molecular, biochemical, genotoxic and microbiological features of importance to selection. Acad J Agr Res. 2015;3(6):081-093.
Mirek Z, Piękoś-Mirkowa H, Zając A, Zając M. Vascular Plants of Poland - A Checklist. Krytyczna lista roślin naczyniowych Polski. 1995.
Cometa MF, Mazzanti G, Romassini L. Sedative and spasmolytic effects of Viburnum tinus L. and its major pure compounds. Phytother Res. 1998;12:89-91.
Schevallier A. The Encyclopedia of Medicinal Plants. Kinddersly D, Ed. London: 1996:148.
Swerdlow JL. Nature’s Medicine. New York: National Geographic Society; 2000.
Iwai K, Kim MIY, Onodera A, Matsue H. Alpha-glucosidase inhibitory and antihyperglycemic effects of polyphenols in the fruit of Viburnum dilatatum Thunb. J Agric Food Chem. 2006;54:4588-4592.
Glasby GS. Dictionary of plants containing secondary metabolites. London:Taylor and Francis;1991.
Plouvier V . Bulletin du Museum National d’Histoire Naturelle. Paris: Adansonia; 1992.
Kim MIY, Iwai K, Onodera A, Matsue H. Identification and antiradicle properties of anthocyanins in fruits of Viburnum dilatatum Thunb. J Agric Food Chem. 2003;51:6173-6177.
Mohamed MA, Marzouk MSA, Moharram FA, El-Sayed MM, Baiuomy AR. Phytochemical constituents and hepatoprotective activity of Viburnum tinus. Phytochemistry. 2005;66:2780-2786.
Yilmaz BS, CitogluGS, Altun ML, Ozbek H. Antinociceptive and anti-inflammatory Activities of Viburnum lantana. Pharm Biol. 2007;45(3):241-245.
Zayachkivska OS, Gzhegotsky MR, Terletska OI, Lutsky DA, Yaschenko AM, Dzhural OR. Influence of Viburnum opulus procyanidines on stress induced gastrointestinal mucosal damage. J Physiol Pharmacol. 2006;57:155-167.
Machida K, Kikuchi M. Studies on the constituents of viburnum species. Part 13. viburnols: Novel triterpenoids with a rearranged dammarane skeleton from Viburnum dilatatum. Tetrahedron Lett. 1996;37:4157–4160.
Machida K, Kikuchi M. Viburnols: Six novel triterpenoids from Viburnum dilatatum. Tetrahedron Lett. 1997;38:571–574.
Kagawa M, Minami H, Nakahara M, Takahashi H, Takaoka S, Fukuyama Y. Oleanane-type triterpenes from Viburnum awabuki . Phytochemistry. 1998;47:1101–1105.
Fukuyama Y, Minami H, Fujii H, Tajima M. Triterpenoids from. Viburnum suspensum. Phytochemistry. 2002;60:765–768.
Zhao Y, Yu ZY, Cong YW, et al. Six new dammarane triterpenoids from Viburnum cylindricum. Helv Chim Acta. 2008;91:1578–1587.
Chen XQ, Li Y, He J, et al. Triterpenoids and diterpenoids from Viburnum chingii. Chem Pharm Bull. 2011;59:496–498.
Jensen SR, Nielsen BJ, Norn V. Iridoids from Viburnum betulifolium. Phytochemistry. 1985;24:487–489.
Hase T, Iwagawa T, Dave MN. Three iridoid glycosides from Viburnum furcatum. Phytochemistry. 1985;24:1323–1327.
Fukuyama Y, Minoshima Y, Kishimoto Y, Chen IS, Takahashi H, Esumi T. Iridoid glucosides and p-coumaroyl iridoids from Viburnum luzonicum and their cytotoxicity. J Nat Prod. 2004;67:1833–1838.
Bae KE, Chong HS, Kim DS, Choi YW, Kim YS, Kim YK. Compounds from Viburnum sargentii Koehne and evaluation of their cytotoxic effects on human cancer cell lines. Molecules. 2010;15:4599–4609.
Fukuyama Y, Kubo M, Esumi T, Harada K, Hioki H. Chemistry and biological activities of vibsane-type diterpenoids. Heterocycles. 2010;81:1571–1602.
Li F-J, Yu J-H, Wang G-C, Zhang H, Yue Jian-Min. Diterpenes and lignans from Viburnum odoratissimum var. odoratissimum. J Asian Nat Prod Res. 2015;17(5):475–481.
Li H, Luo Y, Ma Y, et al. Cytotoxic lignans from Viburnum foetidum. Arch Pharm Res. 2013;36:1211–1214.
Muhaisen HMH, Ilyas M, Mushfiq M, Parveen M, Basudan OA. Flavonoid from Viburnum cotinifolium. J Chem Res 2002;10:480–481.
Uddin G, Alam M, Siddiqui BS, Uddin N, Sadat A, Khan AA, Muhammad N. Characterization and isolation of a new flavonoid from Viburnum grandiflorum. Rec Nat Prod. 2015;9:619–622.
Iwai K, Kim MI, Onodera A, Matsue H. α-Glucosidase inhibitory and antihyperglycemic effects of polyphenols in the fruit of Viburnum dilatatum Thunb. J Agric Food Chem. 2006;54:4588–4592.
Chen XQ, Shao LD, Pal M, Shen Y, Cheng X, Xu G, Peng LY, Wang K, Pan ZH, Li MM, Leng Y, He J, Zhao QS. Hupehenols A-E, selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors from Viburnum hupehense. J Nat Prod. 2015;78:330–334.
Lobstein A, Weniger B, Maléco V, Um BH, Alzate F, Anton R, Polyphenolic content of two Colombian Viburnum species (Caprifoliaceae). Biochem Syst Ecol. 2003;31:95–97.
Mohamed MA, Marzouk MS, Moharram FA, El-Sayed MM, Baiuomy AR, Phyto-chemical constituents and hepatoprotective activity of Viburnum tinus, Phytochemistry. 2005;66:2780–2786.
Zhu XD, Dong XJ, Luo SD, Phenolic compounds from Viburnum cylindricum. Helv Chim Acta. 2005;88:339–342.
Kim MY, Iwai K, Onodera A, Matsue H. Identification and antiradical properties of anthocyanins in fruits of Viburnum dilatatum thumb. J Agric Food Chem. 2003;51:6173–6177.
Seebacher W, Simic N, Weis R, Saf R, Kunert O. Complete assignments of 1H and 13C NMR resonances of oleanolic acid, 18a-oleanolic acid, ursolic acid and their 11-oxo derivatives. Magn Reson Chem. 2003;41:636-638.
Waheed A, Bibi Y, Nisa S, Chaudhary FM, Sahreen S, Zia M. Inhibition of human breast and colorectal cancer cells by Viburnum foetens L. extracts in vitro. Asian Pac J Trop Dis. 2013; 3(1):32-36
Bibi Y, Nisa S, Waheed A, et al. Evaluation of Viburnum foetens for anticancer and antibacterial potential and phytochemical analysis. Afri J Biotechnol. 2010;9:5611–5615.
Fukuyama Y, Minoshima Y, Kishimoto Y, Chen I-S, Takahashi H, Esumi T. Cytotoxic iridoid aldehydes from Taiwanese Viburnum luzonicum. Chem Pharm Bull. 2005;53(1):125-127.
Chen X Q, Li Y, He J, et al. Triterpenoids and diterpenoids from Viburnum chingii. Chem Pharm Bull (Tokyo). 2011;59(4):496-498.
Yu Z-Y, Xiao H, Wang L-M, et al. Natural product Vibsanin A induces differentiation of myeloid leukemia cells through PKC activation. Cancer Res. 2016;76(9):2698-2709.
He J, Peng L-Y, Lin T, et al. Vibsane-type diterpenes from leaves and twigs of Viburnum odoratissimum. Fitoterapia. 2016;109:224–229.
Wang X, Wang W. Cytotoxic and radical scavenging nor-dammarane triterpenoids from Viburnum mongolicum. Molecules. 2013;18:1405-1417.
Nguyen T T, Truong B N, Thi Mai H D, et al. Cytotoxic dammarane-type triterpenoids from the leaves of Viburnum sambucinum. Bioorg Med Chem Letters. 2017;27:1665–1669.
Wang W, Song J, Shi G B, Yu Q G. Cytotoxic nor-dammarane triterpenes from Viburnum hainanense Merr. et Chun. Fitoterapia. 2016;110:8–12.
El-Gamal A A H, Wang S-K, Duh C-Y. New diterpenoids from Viburnum awabuki. J Nat Prod. 2004;67:333-336.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
